NEW WELLLINK
871634
VIBO
871245
MTD
835579
4
REFORMER
833030
5
Hunan Sundy Science And Technology
300515
CN Stock MarketDetailed Quotes
000661 Changchun High-Tech Industries
- 96.05
- -0.88-0.91%
Market Closed Mar 7 15:00 CST
39.18BMarket Cap10.56P/E (TTM)
97.00High95.80Low34.34KlotVolume96.40Open96.93Pre Close330.25MTurnover0.86%Turnover Ratio8.64P/E (Static)407.94MShares128.4852wk High1.68P/B38.38BFloat Cap77.5052wk Low106.62Limit Up399.63MShs Float515.93Historical High87.24Limit Down1.24%Amplitude-3.25Historical Low4.50Dividend TTM96.17Avg Price18.85KlotAsk4.69%Div YieldTTM100Lot Size13.42KlotBid
Changchun High-Tech Industries News
Changchun High-Tech Industry Gets Nod to Amend Growth Hormone Drug
Changchun High-Tech Industries (000661.SZ): The subsidiary's polyethylene glycol recombinant human growth hormone injection has received approval for a supplemental application to increase the approved indications of the same variety in the domestic marke
On March 4, Gelonghui reported that Changchun High-Tech Industries (000661.SZ) announced that recently, its subsidiary—Changchun Jin Sai Pharmaceutical Co., Ltd. (referred to as "Jin Sai Pharmaceutical")—received approval from the National Medical Products Administration for a supplementary application for the already approved indications of its polyethylene glycol recombinant human growth hormone injection (branded as Jin Sai Zeng) in the domestic market. Following the approval from the National Medical Products Administration, two specifications of Jin Sai Zeng (54IU/9.0mg/1.0ml/bottle, 27IU/4.5mg/0.5ml/bottle) have been approved for endogenous use.
Changchun High-Tech Industries (000661.SZ): A cumulative repurchase of 0.67% of shares.
Glory Exchange, March 3 - Changchun High-Tech Industries (000661.SZ) announced that as of February 28, 2025, the company has cumulatively repurchased 2,734,617 shares through a special securities repurchase account via centralized bidding, accounting for 0.67% of the company's total share capital, with the highest Fill Price being 112.25 yuan/share and the lowest Fill Price being 106.62 yuan/share, totaling a transaction amount of 299,997,006.34 RMB (including transaction fees). The implementation of the company's share repurchase complies with relevant laws and regulations as well as the company's established share repurchase plan.
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
A Look At The Intrinsic Value Of Changchun High-Tech Industry (Group) Co., Ltd. (SZSE:000661)
Changchun High-Tech Industries (000661.SZ): The application for the listing of Leuprolide Acetate Injection Emulsion has been accepted.
On February 19, Gelonghui reported that Changchun High-Tech Industries (000661.SZ) announced that its holding subsidiary, Changchun JinSai Pharmaceutical Co., Ltd., received a "Notice of Acceptance" approved and issued by the National Medical Products Administration. Product name: Leuprolide Injection Emulsion. Leuprolide Injection Emulsion (formerly known as "Leuprolide Acetate Suspension Injection" or "LMIS50mg") is a long-acting Gonadotropin-Releasing Hormone Agonist (GnRHa). By continuously releasing leuprolide in the body, it long-term occupies GnRH receptors, desensitizing the corresponding receptors in pituitary target cells, thereby inhibiting the secretion of luteinizing hormone from the pituitary-gonadal axis.
Changchun High-Tech Industry (Group) (SZSE:000661) Investors Are Sitting on a Loss of 57% If They Invested Five Years Ago
Changchun High-Tech Industry Unit Gets China Nod For Clinical Trial of IBD Drug
Changchun High-Tech Industries (000661.SZ): The clinical trial application for the PD-1 monoclonal antibody GenSci120 injection has been approved.
Changchun High-Tech Industries (000661.SZ) released an announcement that recently, the company’s subsidiary—Changchun Jinsai Pharmaceutical Co., Ltd...
Changchun High-Tech Industries (000661.SZ): The application for marketing of Fuxin Qibai monoclonal antibody injection has been accepted.
On January 24, Gelonghui reported that Changchun High-Tech Industries (000661.SZ) announced that its holding subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. (referred to as "Jinsai Pharmaceutical"), recently received the "Acceptance Notification" approved and issued by the National Medical Products Administration. Vuxin Qiba Single Antibody is an IL-1β monoclonal antibody developed by Jinsai Pharmaceutical, which regulates inflammation by blocking the binding of IL-1β to IL-1 receptor I (IL-1RI) and IL-1 receptor II (IL-1RII). It belongs to Class 1 Biological Products for therapeutic use.
Changchun High-Tech Industries (000661.SZ): Relevant nutritional products currently focus mainly on children's health and other areas.
According to the investor interaction platform on January 22, Gelonghui reported that Changchun High-Tech Industries (000661.SZ) is currently focusing its related nutritional products mainly on the field of children's health.
Changchun High-Tech Industry Gets China's Nod to Trial GenSci120 Injection
Changchun High-Tech Industries (000661.SZ): The application for clinical trials of the GenSci120 injection by the subsidiary has been approved.
On January 16, Gelonghui reported that Changchun High-Tech Industries (000661.SZ) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. (hereinafter referred to as "Jinsai Pharmaceutical"), has received the "Drug Clinical Trial Approval" issued by the National Medical Products Administration. The clinical trial application for Jinsai Pharmaceutical's GenSci120 injection has been approved. GenSci120 is a humanized anti-PD-1 monoclonal antibody developed by Jinsai Pharmaceutical, and the antibody type is IgG1, which works by binding to PD-1 and activating the PD-1 inhibitory signaling pathway.
Changchun High-Tech Industry (Group) (SZSE:000661) Seems To Use Debt Quite Sensibly
Changchun High-Tech Industries (000661.SZ): Kaimeisi and Xinfagroup signed a Global Strategy cooperation framework agreement.
On January 6, Gelonghui reported that Changchun High-Tech Industries (000661.SZ) announced that to establish a good, stable, and deep cooperation relationship, achieve resource sharing and mutual advantages, and enhance the core competitiveness of both sides in their respective fields, the company’s wholly-owned subsidiary Changchun Kaimisi Pharmaceutical Co., Ltd. (referred to as "Kaimisi") has signed a "Global Strategy Cooperation Framework Agreement" with Changchun New District Development Group Co., Ltd. (referred to as "New Development Group"). Under the premise of meeting both sides' risk control requirements and in accordance with market rules, the New Development Group intends to conduct deep cooperation with Kaimisi through means including but not limited to equity participation through rental debt.
Changchun High-Tech Industries (000661.SZ): The cooperative product Pediatric Gold Cough Granules has been approved for sale domestically.
Changchun High-Tech Industries (000661.SZ) issued an announcement, recently, the company's controlling subsidiary Changchun Jinsai Pharmaceutical Co., Ltd...
Changchun High-Tech Industries (000661.SZ) has repurchased a total of 0.67% of its shares, spending approximately 0.3 billion yuan.
Changchun High-Tech Industries (000661.SZ) announced that as of December 31, 2024, the company has cumulatively...
Changchun High-Tech Industry Group Gets Approval to Conduct Clinical Trials for Vaccine
Changchun High-Tech Industries (000661.SZ): The international pharmaceutical industrial park is not yet fully formally put into production.
On December 26, Geloonghui reported that Changchun High-Tech Industries (000661.SZ) stated on its investor interaction platform that the international pharmaceutical industrial park has not yet fully started production. The company's newly constructed capacity has fully taken into account the production demands for the near future, and the relevant capacity should be based on the final quantities after formal production commences.
Are Robust Financials Driving The Recent Rally In Changchun High-Tech Industry (Group) Co., Ltd.'s (SZSE:000661) Stock?